Detection of somatostatin receptors in human osteosarcoma.
BACKGROUND
The location of osteosarcoma in the metaphysis as well as the age of the patients during the most rapid tumour growth suggest that factors related to skeletal growth are involved in the pathogenesis of this tumour. In this aspect this study aims to detect somatostatin receptors in human osteosarcomas and correlate this finding with the clinical outcome of the tumour.


METHODS
Immunohistochemical staining for the presence of somatostatin receptors as well as overall survival and disease free survival rates were retrospectively studied in twenty-nine osteosarcoma patients.


RESULTS
Four osteosarcomas with several aggressive biologic behaviour expressed somatostatin receptors. In these four young patients the event free rate was 0% and the overall survival rate was 50% at 4, 3 years. In contrast the event free survival rate of the twenty-five patients with negative somatostatin receptor status was 72% with an overall survival rate of 76% at 4,3 years.


CONCLUSIONS
The present study demonstrates the existence of somatostatin receptors in human osteosarcoma. Tumours expressing somatostatin receptors seemed to be aggressive with a very low disease free and overall survival rate compared to osteosarcoma with negative receptor status.
Ioannou
Markos
M
Department of Orthopaedic Surgery, Cancer Hospital, Pireus, Greece. markosioannou@yahoo.gr
Papagelopoulos
Panayiotis J
PJ
Papanastassiou
Ioannis
I
Iakovidou
Ioanna
I
Kottakis
Stamatios
S
Demertzis
Nikolaos
N
D000293:Adolescent; D000328:Adult; D001859:Bone Neoplasms / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D012516:Osteosarcoma / Q000378:metabolism*; D017481:Receptors, Somatostatin / Q000096:biosynthesis*; D012189:Retrospective Studies; D016019:Survival Analysis
D017481:Receptors, Somatostatin
J Clin Oncol. 1997 Jan;15(1):76-84
8996127
Clin Cancer Res. 2002 Jul;8(7):2406-12
12114446
J Histochem Cytochem. 1976 Jul;24(7):883-97
60437
J Histochem Cytochem. 1976 Jul;24(7):872-82
60436
J Clin Endocrinol Metab. 1990 Mar;70(3):661-9
1968467
Br J Cancer. 1994 Nov;70(5):886-92
7947094
J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):27-35
1356016
Clin Orthop Relat Res. 1973 Nov-Dec;(97):64-8
4521231
Ann Oncol. 1998 Aug;9(8):893-9
9789613
Cancer. 2006 Mar 1;106(5):1154-61
16421923
Acta Orthop. 2007 Jun;78(3):377-84
17611853
Recent Results Cancer Res. 1976;(54):92-103
189372
J Biol Chem. 1990 Jun 5;265(16):8989-92
2160951
J Pediatr Hematol Oncol. 2002 Aug-Sep;24(6):440-6
12218590
J Clin Endocrinol Metab. 1992 Mar;74(3):543-7
1346787
Int J Cancer. 1996 Mar 15;65(6):870-4
8631606
J Clin Oncol. 2000 Dec 15;18(24):4016-27
11118462
J Clin Oncol. 1992 Jan;10(1):5-15
1370176
Cancer Biother Radiopharm. 2003 Oct;18(5):847-51
14629833
Am J Vet Res. 2000 Jun;61(6):646-50
10850839
Pediatr Blood Cancer. 2004 Jan;42(1):59-63
14752796
Cell Tissue Res. 1977 Dec 28;185(4):465-79
342100
Clin Orthop Relat Res. 1986 Mar;(204):9-24
3456859
Eur J Cancer. 1997 Sep;33(10):1611-8; discussion 1618-9
9389923
Pathology. 1976 Apr;8(2):157-9
1067559
Cancer. 2006 Jan 15;106(2):403-12
16353204